When a Monoclonal Gammopathy Is Not Multiple Myeloma
Apr 8, 2022 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority of MGUS cases arise from a malignant ...
Nov 1, 2021 · ASCO special articles Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Low-Grade Prostate Cancer: Time to Stop Calling It Cancer
Apr 18, 2022 · A common definition of cancer is a “malignant tumor (which) can invade and destroy adjacent structures and spread to distant sites,” 8 a view generally shared by the nonmedical public. 9 Although GS6 meets the pathologic criteria of a cancer (invasion of the stroma), without the simultaneous presence of higher-grade disease (GS ≥ 7; ie, Grade Group ≥ 2), it is effectively incapable of ...
ASCO Daily News
Podcast: Advances in Immunotherapy for Melanoma and Beyond. Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the use of TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. More ASCO Daily News Podcasts.
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, …
Nov 10, 2021 · In the adjuvant setting, where DFS is used as an endpoint in clinical trials, the risks of therapies are immediate. Moreover, there is a guarantee that treatment in this context will impair quality of life (QOL); in the absence of cancer and cancer symptoms, it is not possible for treatment to improve QOL. Although risks are virtually certain ...
Lorlatinib Versus Crizotinib in Patients With Advanced
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy recommended for patients with ALK-positive non–small cell lung cancer (NSCLC). 1 Lorlatinib is a brain-penetrant, third-generation ALK TKI that has greater coverage of ALK resistance mutations than second-generation ALK inhibitors. 2,3 In the phase III CROWN study, lorlatinib showed ...
Organ Preservation in Patients With Rectal Adenocarcinoma …
Apr 28, 2022 · Neoadjuvant chemoradiotherapy (CRT), total mesorectal excision (TME), and adjuvant chemotherapy is a standard treatment for patients with locally advanced rectal adenocarcinoma. 1 This multimodality treatment, although effective in achieving tumor control, is associated with significant morbidity, with bowel, urinary, and sexual dysfunction that can impair patients' quality of life permanently ...
Advances in Salvage Radiotherapy for Prostate Cancer: Dose, Field …
Feb 2, 2023 · Dr. Luca Valle. Key Points: Rigorous randomized trials have evaluated critical aspects of salvage radiotherapy, including radiation field size, radiation dose escalation, the optimal use and duration of concomitant hormone therapy, and the utility of pretreatment advanced imaging. Preradiotherapy prostate-specific antigen remains an important ...
KEYNOTE-048: A Phase III Study of First-Line Pembrolizumab for ...
May 22, 2019 · Dr. Heath Skinner. Article Highlights. Pembrolizumab monotherapy significantly improved overall survival in patients with squamous cell carcinoma of the head and neck (HNSCC) and a PD-L1 combined positive score (CPS) of > 1 and > 20 compared with platinum/5-FU plus cetuximab.
EMERALD-1: A phase 3, randomized, placebo-controlled study of ...
Jan 22, 2024 · Background: For >20 years, TACE has been a standard of care for embolization-eligible uHCC; however, most people with uHCC treated with TACE progress within 1 year. Embolization creates a proinflammatory tumor microenvironment and increases VEGF signals; clinical studies have established the role of immune checkpoint inhibitors (ICIs; e.g. D) and VEGF inhibitors (e.g. B) in advanced HCC.